BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sové RJ, Verma BK, Wang H, Ho WJ, Yarchoan M, Popel AS. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. J Immunother Cancer 2022;10. [PMID: 36323435 DOI: 10.1136/jitc-2022-005414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Psilopatis I, Damaskos C, Garmpi A, Sarantis P, Koustas E, Antoniou EA, Dimitroulis D, Kouraklis G, Karamouzis MV, Vrettou K, Marinos G, Kontzoglou K, Garmpis N. FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? Int J Mol Sci 2023;24. [PMID: 36769004 DOI: 10.3390/ijms24032685] [Reference Citation Analysis]
2 Yang J, Jiang S, Chen Y, Zhang J, Deng Y. Adjuvant ICIs Plus Targeted Therapies Reduce HCC Recurrence after Hepatectomy in Patients with High Risk of Recurrence. Curr Oncol 2023;30:1708-19. [PMID: 36826093 DOI: 10.3390/curroncol30020132] [Reference Citation Analysis]
3 Lominadze Z, Hill K, Shaik MR, Canakis JP, Bourmaf M, Adams-Mardi C, Abutaleb A, Mishra L, Shetty K. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review. Int J Mol Sci 2023;24. [PMID: 36768686 DOI: 10.3390/ijms24032358] [Reference Citation Analysis]
4 Edeline J, Meyer T, Blanc JF, Raoul JL. New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations. Cancers (Basel) 2022;14. [PMID: 36497349 DOI: 10.3390/cancers14235868] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]